

- infectious, 369  
 in infective endocarditis, 76e-12f, 818, 818f, 825  
 mesenteric arterial, 1980, 1980t  
 platelet, 40e-4  
 pulmonary. *See* Pulmonary embolism (PE)  
 retinal, 40e-4  
 talc, 40e-4
- Embospheres, 550
- Embryologic development  
 of blood vessels, 265e-1  
 of cardiovascular system, 265e-11-12, 265e-11f  
 of heart, 1520  
 of kidney, 332e-1-2, 332e-1f, 333e-1
- Embryonal carcinoma  
 ovarian, 594-595  
 paraneoplastic syndromes in, 609t  
 parasellar, 2264  
 testicular, 588
- Embryonic carcinoma cells, 453t
- Embryonic germ cells, 453, 453t
- Embryonic stem cells, 454-455  
 ethical issues, 90e-4  
 genes in regulation of, 455  
 patient-specific, 454  
 potency of, 454f  
 sources of, 90e-1-2, 453t  
 in tissue engineering, 92e-1  
 for tissue repair, 90e-1-2
- Emergent behavior, in biologic systems, 87e-2
- Emerin proteins, 1554
- Emery-Dreifuss muscular dystrophy, **462e-9**  
 clinical features of, 462e-5t, 462e-9  
 diagnosis of, 462e-9  
 genetic considerations in, 435, 436t, 462e-5t  
 pathogenesis of, 462e-9, 462e-9f  
 treatment of, 462e-9
- Emesis, 103e-25, 258. *See also* Nausea and vomiting
- Emetine, 203, 246e-4t, 246e-8, 2199
- EMG. *See* Electromyography (EMG)
- Emmetropia, 195
- Emollients, 344, 346
- Empagliflozin, 2414t
- Empyema. *See also* Chronic obstructive pulmonary disease (COPD)  
 centriacinar, 1701  
 chest radiograph in, 308e-5f  
 CT in, 308e-5f  
 cyanosis in, 249  
 diagnosis of, 1664f  
 panacinar, 1701  
 pathophysiology of, 306e-3  
 pulmonary function values in, 306e-5-6, 306e-5f
- Empysematous cholecystitis, 2081
- Employee health service, 918
- Empty sella, 2257
- Empyema  
 abdominal pain in, 106t  
 actinomycotic, 1089, 1089f  
 anaerobic bacterial, 1098-1099  
 in cholecystitis, 2081  
 definition of, 1717  
 in pneumococcal pneumonia, 951  
 in streptococcal pneumonia, 968  
 subdural. *See* Subdural empyema  
 tuberculous, 1110
- EMS. *See* Eosinophilia-myalgia syndrome (EMS)
- Emtricitabine (FTC)  
 adverse effects of, 1274t  
 for HIV infection, 1274t, 1277  
 molecular structure of, 1276f, 1277  
 resistance to, 1277, 1279f
- Enalapril, 371, 1507, 1512t
- Enalaprilat, 1627t, 1641
- Enamel, mottled, 236
- Enamel hypoplasia, 236
- Encephalitis  
 amebic, 896  
 with antibodies to cell-surface or synaptic proteins, 614t, 617, 617f  
 approach to the patient, 883-884, 884-885f  
 autoimmune, 896  
 brainstem, 614t, 616  
 in cancer patient, 488, 488t  
 chronic  
 progressive multifocal  
 leukoencephalopathy. *See* Progressive multifocal leukoencephalopathy (PML)  
 progressive rubella panencephalitis, 900  
 subacute sclerosing panencephalitis, 900, 1298  
 cortical, 616  
 delirium in, 169  
 EEG in, 442e-1f  
 focal, 614t, 616-617, 616f  
 global considerations in, 896  
 granulomatous amebic, 1368  
 hyponatremia in, 299  
 in influenza, 1212  
*L. monocytogenes*, 983  
 limbic, 441e-1f, 616, 616f, 2607  
*M. pneumoniae*, 1164  
 measles-associated, 1298  
 pinworm, 896  
 in rabies, 1301  
 in Rocky Mountain spotted fever, 1156  
 toxoplasmic, 1401-1402, 1402f  
 viral, **893**  
 approach to the patient, 883-884, 884-885f  
 arboviral, 1314-1317. *See also* West Nile virus infection  
 clinical features of, 893  
 CMV, 1192  
 definition of, 893  
 diagnosis of, 766t, 894-895, 895f, 895t  
 differential diagnosis of, 895-896  
 enteroviral, 1291, 1291t  
 epidemiology of, 896  
 etiology of, 891t, 893-894  
 HHV-6, 1194  
 HSV. *See* Herpes simplex virus (HSV) infections, encephalitis  
 mumps-associated, 231e-2, 231e-3, 893  
 sequelae of, 898  
 tick-borne, 1316-1317  
 treatment of, 896-898
- Encephalitozoon* spp., 245e-4t, 246e-9, 1408
- Encephalomyelitis  
 acute disseminated (ADEM), 441e-26f, **2673**  
 experimental allergic, 444e-5, 444e-6f  
 paraneoplastic, 372e-25t, 614t, 616-617  
 postinfectious, 1298, 2673  
 with rigidity, 617
- Encephalopathy. *See also* Delirium  
 chemotherapy-induced, 607, 607t  
 chronic traumatic, 457e-4  
 Hashimoto's, 441e-29f, 453e-5  
 hepatic, **2066**  
 asterix in, 1782  
 MRI in, 441e-42f  
 pathophysiology of, 1773  
 physical examination in, 1992  
 high-altitude. *See* High-altitude cerebral edema (HACE)  
 HIV. *See* HIV infection, neurologic disease in  
 hypertensive, 1615, 1626-1627, 2584  
 hyponatremic, 300  
 hypoxic-ischemic, 1773, 1781-1782, 1782f, 2559  
 in Lyme disease, 1151  
 in malaria, 780t, 783-784, 1373, 1373f, 1374t  
 metabolic, 178, 1772-1773, 1782  
 posterior reversible, 2568  
 sepsis-associated, 1782
- Enchondromatosis (Ollier's disease), 426e-7, 594
- Enderterectomy  
 aortoiliac, 1645  
 carotid, 2571
- Endemic goiter, 2301
- Endemic syphilis, 207e-2, 207e-2f, 207e-2t, 207e-3
- Endemic (murine) typhus  
 clinical features of, 127, 128t, 1155t, 1159  
 diagnosis of, 1159  
 epidemiology of, 1155t, 1158-1159
- etiology of, 1155t  
 treatment of, 1159
- Endocarditis  
 acute, 816  
 infective. *See* Infective endocarditis  
 Libman-Sacks, 2136  
 marantic, 138, 367, 816  
 nonbacterial thrombotic, 816, 2566t  
 subacute, 816
- Endocrine, 2251
- Endocrine disorders, **2251**. *See also specific disorders*  
 clinical evaluation of, 2252-2253  
 fatigue in, 152  
 hypothermia in, 478e-1, 478e-2t  
 in lung cancer, 511  
 myopathy in, 462e-18-19  
 paraneoplastic. *See* Paraneoplastic syndromes, endocrinologic  
 pathologic mechanisms of, 2251-2252  
 in pregnancy, 47-48  
 prevalence of, 2254t  
 screening/testing for, 2253, 2254t  
 types of, 2251, 2252t
- Endocrine glands, 2251. *See also specific glands*
- Endocrine tumors  
 gastrointestinal. *See* Gastrointestinal neuroendocrine tumors (GI-NETS)  
 pancreatic. *See* Pancreatic neuroendocrine tumors (pNETs)
- Endocrinology, **2251**
- Endodermal sinus tumor, testicular, 588
- End-of-life care, **55**. *See also* Terminally ill patient  
 advance care planning in, 58-59, 59t  
 assessment of patient in, 56-57  
 for cancer patient, 119e-4, 475  
 care during last hours, 68-69, 68f, 69t  
 communicating bad news to patient in, 57--58, 57t  
 continuous goal assessment in, 48  
 epidemiology of, 55-56, 56f  
 euthanasia in, 67-68, 67t  
 futile care in, 67  
 future directions, 70  
 hospice care, 56, 70  
 outcome measures for, 70  
 physician-assisted suicide, 67-68, 67t  
 principles of, 4  
 withdrawing/withholding life-sustaining treatment during, 66-67. *See also* Withdrawal/withholding of care
- Endolymphatic hydrops. *See* Ménière's disease
- Endometrial cancer, **596**  
 back pain in, 118  
 clinical features of, 596-597  
 deaths from, 467t, 469f, 596  
 epidemiology of, 596  
 genetic considerations in, 596  
 granulosa cell tumor and, 594  
 incidence of, 467t, 468f  
 oral contraceptives and, 2391t  
 postmenopausal hormone therapy and, 2383, 2384t, 2386  
 prognosis of, 593t, 597  
 risk factors for, 596  
 as second malignancy in breast cancer survivor, 623  
 staging of, 593t, 596  
 tamoxifen use and, 531, 623  
 treatment of, 597
- Endometriosis  
 clinical features of, 118, 338, 2388  
 definition of, 2388  
 diagnosis of, 338  
 etiology of, 338  
 infertility due to, 2388  
 vs. interstitial cystitis/bladder pain syndrome, 60e-3  
 pulmonary, 246  
 treatment of, 2389
- Endometritis  
 actinomycotic, 1089  
 alone, vs. with salpingitis, 877